SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-18-138837
Filing Date
2018-04-27
Accepted
2018-04-27 16:06:56
Documents
9
Effectiveness Date
2018-04-27

Document Format Files

Seq Description Document Type Size
1 DEFA14A d506171ddefa14a.htm DEFA14A 31999
2 GRAPHIC g506171dsp002a.jpg GRAPHIC 16949
3 GRAPHIC g506171dsp002b.jpg GRAPHIC 10616
4 GRAPHIC g506171dsp002c.jpg GRAPHIC 3644
5 GRAPHIC g506171dsp002d.jpg GRAPHIC 3932
6 GRAPHIC g506171dsp002f.jpg GRAPHIC 2440
7 GRAPHIC g506171dsp002g.jpg GRAPHIC 2495
8 GRAPHIC g506171dsp002h.jpg GRAPHIC 660
9 GRAPHIC g506171dsp002i.jpg GRAPHIC 853
  Complete submission text file 0001193125-18-138837.txt   91533
Mailing Address 430 EAST 29TH STREET NEW YORK NY 10016
Business Address 430 EAST 29TH STREET NEW YORK NY 10016 212-923-3344
Intra-Cellular Therapies, Inc. (Filer) CIK: 0001567514 (see all company filings)

IRS No.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36274 | Film No.: 18783881
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences